Neisseria meningitidisserogroup B: laboratory correlates of protection
Open Access
- 1 October 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in FEMS Immunology & Medical Microbiology
- Vol. 34 (2) , 89-96
- https://doi.org/10.1111/j.1574-695x.2002.tb00608.x
Abstract
Meningococcal disease in the Western countries is frequently caused by Neisseria meningitidis serogroup B. Major efforts have been made to develop aKeywords
This publication has 72 references indexed in Scilit:
- Antibody Avidity and Immunoglobulin G Isotype Distribution following Immunization with a Monovalent Meningococcal B Outer Membrane Vesicle VaccineInfection and Immunity, 2002
- Immune Response Induction and New Effector Mechanisms Possibly Involved in Protection Conferred by the Cuban Anti-Meningococcal BC VaccineInfection and Immunity, 2001
- Importance of Complement Source in Measuring Meningococcal Bactericidal TitersClinical and Diagnostic Laboratory Immunology, 2001
- A mouse model utilising human transferrin to study protection againstNeisseria meningitidisserogroup B induced by outer membrane vesicle vaccinationFEMS Immunology & Medical Microbiology, 1999
- Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccineVaccine, 1999
- Identification of T cell epitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis.The Journal of Experimental Medicine, 1992
- Immunization against serogroup B meningococciAPMIS, 1991
- Killing of Neisseria meningitidis by Human Neutrophils: Implications for Normal and Complement-Deficient IndividualsThe Journal of Infectious Diseases, 1987
- N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis.The Journal of Experimental Medicine, 1987
- Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of AgeNew England Journal of Medicine, 1977